Page 2 - Nasdaq Cmpx News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Compass Therapeutics (NASDAQ:CMPX – Get Free Report) and Genenta Science (NASDAQ:GNTA – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, risk, institutional ownership, profitability and valuation. Analyst Recommendations This is a breakdown of […]

BOSTON, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company...

Compass Therapeutics, Inc. (NASDAQ:CMPX – Get Rating) has been given an average rating of “Buy” by the seven ratings firms that are presently covering the company, MarketBeat.com reports. Six investment analysts have rated the stock with a buy rating. The average twelve-month price target among brokers that have updated their coverage on the stock in […]

BOSTON, June 01, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company...

Compass Therapeutics, Inc. (NASDAQ:CMPX – Get Rating) was the recipient of a significant drop in short interest during the month of May. As of May 15th, there was short interest totalling 2,060,000 shares, a drop of 5.9% from the April 30th total of 2,190,000 shares. Approximately 3.1% of the company’s stock are sold short. Based […]